Valproic acid and carbamazepine: A successful antipsychotic medication? The problem of diagnosis and its relevance for therapy

Psychopathology

Volumn 32, Issue 5, 1999, Pages 235-241

  Gutiérrez, Karin ^a   Walter, Henriette ^b   Bankier, Bettina ^b  

^a UNIVERSITY OF VIENNA   (Austria)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENZODIAZEPINE; CARBAMAZEPINE; CHLORPROTHIXENE; CLOZAPINE; HALOPERIDOL; LAMOTRIGINE; NEUROLEPTIC AGENT; TRANQUILIZER; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID;

ADULT; ARTICLE; CASE REPORT; DEPRESSION; FEMALE; HUMAN; MANIC DEPRESSIVE PSYCHOSIS; PARANOID PSYCHOSIS; REMISSION; SYMPTOMATOLOGY;

EID: 19244375244     PISSN: 02544962     EISSN: None     Source Type: Journal    
DOI: 10.1159/000029095     Document Type: Article

References (20)

1. ICD-9th Revision: Internationale Klassifikation psychischer Störungen ICD-9. Genf, WHO. 1978.
2. Günther W, Baghai T, Naber D, Spatz R, Hippius H: EEG alterations and seizures during treatment with clozapine. Pharmacopsychiatry 1993;26:69-74.
3. nd ed, World Psychiatric Association, 1992.
4. Dilling H, Mombour W, Schmidt MH: Internationale Klassifikation psychischer Störungen ICD-10. Huber, 1993.
5. Saß H, Wittchen H-U Zaudig M: Diagnostisches und Statistisches Manual Psychischer Störungen DSM-IV. Hogrefe, 1994.
6. Jaspers K: General Psychopathology. Chicago, University of Chicago Press, 1963.
7. Ekblom B, Eriksson K, Lindstrom LH: Supersensitivity psychosis in schizophrenic patients after sudden clozapine withdrawal. Psychopharmacology 1984;83:293-294.
8. Meynard JA, Bernadet R, Sanchez MF, Morel P: Schizophrenia, affective symptoms and clozapine. Encephale 1995;3:41-47.
9. Risby ED, Epstein CM, Jewart RD, Nguyen BV, Morgan WN, Risch SC, Thrivikraman KV, Lewine RL: Clozapine-induced abnormalities and clinical response to clozapine. J Neuropsychiatry Clin Neurosci 1995;7:466-470.
10. Treves IA, Neufeld NY: EEG abnormalities in clozapine-treated schizophrenic patients. Eur Neuropsychopharmacol 1996;6:93-94.
11. Kusumakar VK, Lakshmi NY, Haslam DRS, Parikh SV, Matte R, Silverstone PH, Sharma V: Treatment of mania, mixed state and rapid cycling. Can J Psychiatry 1997;42:79-86 (S).
12. Srisurapanont M, Yatham LN, Zis AP: Treatment of acute bipolar depression: A review of the literature. Can J Psychiatry 1995;40:533-544.
13. Christison GW, Kirch DG, Wyatt RJ: When symptomes persist: Choosing among alternative somatic treatments for schizophrenia. Schizophr Bull 1991;17:217-245.
14. Baldessarini RJ, Cohen BM, Teicher MH: Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychosis. Arch Gen Psychiatry 1988;45:79-91.
15. Chouinard G, Jones BD: Neuroleptic-induced supersensitivity psychosis: Clinical and pharmacologic characteristics. Am J Psychiatry 1980;137:16-21.
16. Grace AA: Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: A hypotheses for the etiology of schizophrenia. Neuroscience 1991;41:1-24.
17. Janzarik W: Strukturdynamische Grundlagen der Psychiatrie. Stuttgart, Enke 1988.
18. Berner P: Development of the manic depressive concept in German language psychiatry. Encephale 1992;18: 5-8.
19. Berner P: Conceptualisation of schizophrenia: The symptom-oriented approach. Psychopathology 1997;30: 251.
20. Bryson-Brockmann W, Roll D: Single case experimental designs in medical education: An innovative research method. Acad Med 1996;71:78-85.